Prostate hyperplasia caused by long-term obesity is characterized by high deposition of extracellular matrix and increased content of MMP-9 and VEGF

International Journal of Experimental Pathology

Volumn 96, Issue 1, 2015, Pages 21-30

  Silva, Silas Amâncio ^a   Gobbo, Marina Guimarães ^b   Pinto Fochi, Maria Etelvina ^b   Rafacho, Alex ^c   Taboga, Sebastião Roberto ^b   Almeida, Eduardo Alves ^b   Góes, Rejane Maira ^b   Ribeiro, Daniele Lisboa ^a  

^a FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^c FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Androgen receptor; Hyperplasia; MMP 9; Obesity; Prostate; Stromal remodelling

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANDROGEN RECEPTOR; CATALASE; CHONDROITIN SULFATE; ESTROGEN RECEPTOR; GELATINASE A; GELATINASE B; GLUCOSE; GLUTATHIONE TRANSFERASE; INSULIN; TESTOSTERONE; VASCULOTROPIN; VIMENTIN; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; MALONALDEHYDE; MMP9 PROTEIN, RAT; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL; CELL DENSITY; CELL MIGRATION; CELL PROLIFERATION; COLLAGEN FIBER; CONTROLLED STUDY; ENZYMATIC ASSAY; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; FEEDING; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; LIPID DIET; MALE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATE VENTRAL LOBE; PROTEIN CONTENT; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; TESTOSTERONE BLOOD LEVEL; WESTERN BLOTTING; ANIMAL; BLOOD; COMPLICATION; DISEASE MODEL; ENZYMOLOGY; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY; PROSTATE; PROSTATIC HYPERPLASIA; RISK FACTOR; STROMA CELL; TIME FACTOR; TUMOR MICROENVIRONMENT; UPREGULATION; WISTAR RAT;

ANIMALS; BIOMARKERS; BLOOD GLUCOSE; CATALASE; CELL PROLIFERATION; CELLULAR MICROENVIRONMENT; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX; GLUTATHIONE TRANSFERASE; INSULIN; MALE; MALONDIALDEHYDE; MATRIX METALLOPROTEINASE 9; OBESITY; OXIDATION-REDUCTION; PROSTATE; PROSTATIC HYPERPLASIA; RATS, WISTAR; RECEPTORS, ANDROGEN; RISK FACTORS; STROMAL CELLS; TESTOSTERONE; TIME FACTORS; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84923487762     PISSN: 09599673     EISSN: 13652613     Source Type: Journal    
DOI: 10.1111/iep.12107     Document Type: Article

References (49)

1. Arsova-Sarafinovska Z., Eken A., Matevska N. et al. (2009) Increased oxidative/nitrosative stress and decreased antioxidant enzyme activities in prostate cancer. Clin. Biochem. 42, 1228-1235.
2. Bergers G., Brekken R. & McMahon G. (2000) Matrix metalloproteinase- 9 triggers the angiogenic switch during carcinogenesis. Nat. Cell. Biol. 2, 737-744.
3. Beutler E. (1975) Red Cell Metabolism: a Manual of Biochemical Methods, 3rd edn, pp. 342. New York: Grune and Straton.
4. Bradford M.M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
5. Bruni-Cardoso A., Vilamaior P.S., Tabga S.R. & Carvalho H.F. (2008) Localized matrix metalloproteinase (MMP)-2 and MMP-9 activity in the rat ventral prostate during the first week of postnatal development. Histochem. Cell Biol. 129, 805-815.
6. Bruni-Cardoso A., Lynch C.C., Rosa-Ribeiro R., Matrisian L.M. & Carvalho H.F. (2010) MMP-2 contributes to the development of the mouse ventral prostate by impacting epithelial growth and morphogenesis. Dev. Dyn. 239, 2386-2392.
7. Cooke M.S., Evans M.D., Dizdaroglu M. & Lunec J. (2003) Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J. 17, 1195-1214.
8. Corona G., Vignozzi L., Rastrelli G., Lotti F., Cipriani S. & Maggi M. (2014) Benign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunctions. Int. J. Endocrinol. 2014, 329456.
9. Crowe F.L., Key T.J., Appleby P.N., Travis R.C., Overvad K., Jakobsen M.U., Johnsen N.F., Tjønneland A., Linseisen J., Rohrmann S., Boeing H., Pischon T., Trichopoulou A., Lagiou P., Trichopoulos D., Sacerdote C., Palli D., Tumino R., Krogh V., Bueno-de-Mesquita H.B., Kiemeney L.A., Chirlaque M.D., Ardanaz E., Sánchez M.J., Larrañaga N., González C.A., Quirós J.R., Manjer J., Wirfält E., Stattin P., Hallmans G., Khaw K.T., Bingham S., Ferrari P., Slimani N., Jenab M., Riboli E. (2008) Dietary fat intake and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr. 87(5), 1405-13.
10. Curran S. & Murray G.I. (1999) Matrix metalloproteinases in tumour invasion and metastasis. J. Pathol. 189, 300-308.
11. Deroo B.J. & Korach K.S. (2006) Estrogen receptors and human disease. J. Clin. Invest. 116, 561-570.
12. Draper H.H. & Hadley M. (1990) Malondialdehyde determination as index of lipid peroxidation. Methods Enzymol. 186, 421-431.
13. Fibbi B., Penna G., Morelli A., Adorini L. & Maggi M. (2010) Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int. J. Androl. 33, 475-488.
14. Gill S.E. & Parks W.C. (2008) Metalloproteinases and their inhibitors: regulators of wound healing. Int. J. Biochem. Cell Biol. 40, 1334-1347.
15. Gobbo M.G., Ribeiro D.L., Taboga S.R., de Almeida E.A. & Góes R.M. (2012) Oxidative stress markers and apoptosis in the prostate of diabetic rats and the influence of vitamin C treatment. J. Cell. Biochem. 113, 2223-2233.
16. Góes R.M., Zanetoni C., Tomiosso T.C., Ribeiro D.L. & Taboga S.R. (2007) Surgical and chemical castration induce differential histological response in prostate lobes of Mongolian gerbil. Micron 38, 231-236.
17. Goulas A., Hatzichristou D.G., Karakiulakis G., Mirtsou-Fidani V., Kalinderis A. & Papakonstantinou E. (2000) Benign hyperplasia of the human prostate is associated with tissue enrichment in chondroitin sulphate of wide size distribution. Prostate 44, 104-110.
18. Hartman J., Ström A. & Gustafsson J.Å. (2012) Current concepts and significance of estrogen receptor β in prostate cancer. Steroids 77, 1262-1266.
19. Keen J.H., Habig W.H. & Jakoby W.B. (1976) Mechanism for several activities of the glutathione S-transferases. J. Biol. Chem. 251, 6183-6188.
20. Kim S.H., Turnbull J. & Guimond S. (2011) Extracellular matrix and cell signaling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. J. Endocrinol. 209, 139-151.
21. Kopelman P.G. (2000) Obesity as a medical problem. Nature 404, 635-643.
22. Lima-Leopoldo A.P., Leopoldo A.S., Sugizaki M.M. et al. (2011) Myocardial dysfunction and abnormalities in intracellular calcium handling in obese rats. Arq. Bras. Cardiol. 97, 232-240.
23. Morrissey C., Buser A., Scolaro J., O'Sullivan J., Moquin A. & Tenniswood M. (2002) Changes in hormone sensitivity in the ventral prostate of aging sprague-dawley rats. J. Androl. 23, 341-351.
24. Mott J.D. & Werb Z. (2004) Regulation of matrix biology by matrix metalloproteinases. Curr. Opin. Cell Biol. 16, 558-564.
25. Pelser C., Mondul A.M., Hollenbeck A.R. & Park Y. (2013) Dietary fat, fatty acids, and risk of prostate cancer in the NIH-AARP diet and health study. Cancer Epidemiol. Biomarkers Prev. 22, 697-707.
26. Peterson G.L. (1977) A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal. Biochem. 83, 346-356.
27. Prins G.S., Birch L., Couse J.F., Choi I., Katzenellenbogen B., Korach K.S. (2001) Estrogen imprinting of the developing prostate gland is mediated through stromal estrogen receptor alpha: studies with alphaERKO and betaERKO mice. Cancer Res. 61, 6089-6097.
28. Ribeiro D.L., Caldeira E.J., Cândido E.M., Manzato A.J., Taboga S.R. & Cagnon V.H. (2006) Prostatic stromal microenvironment and experimental diabetes. Eur. J. Histochem. 50, 51-60.
29. Ribeiro D.L., Marques S.F., Alberti S. et al. (2008) Malignant lesions in the ventral prostate of alloxan-induced diabetic rats. Int. J. Exp. Pathol. 89, 276-283.
30. Ribeiro D.L., Taboga S.R. & Góes R.M. (2009) Diabetes induces stromal remodelling and increase in chondroitin sulphate proteoglycans of the rat ventral prostate. Int. J. Exp. Pathol. 90, 400-411.
31. Ribeiro D.L., Pinto M.E., Maeda S.Y., Taboga S.R. & Góes R.M. (2012a) High fat-induced obesity associated with insulin resistance increases the FGF-2 content and causes stromal hyperplasia on the rat ventral prostate. Cell Tissue Res. 349, 577-588.
32. Ribeiro D.L., Pinto M.E., Rafacho A. et al. (2012b) High-fat diet obesity associated with insulin resistance increases cell proliferation, estrogen receptor, and PI3K proteins in rat ventral prostate. J. Androl. 33, 854-865.
33. Romberger D.J. (1997) Fibronectin. Int. J. Biochem. Cell Biol. 29, 939-943.
34. Rowley D.R. (1999) What might a stromal response mean to prostate cancer progression? Cancer Metastasis Rev. 17, 411-419.
35. Rundle A., Jankowski M., Kryvenko O.N., Tang D. & Rybicki B.A. (2013) Obesity and future prostate cancer risk among men after an initial benign biopsy of the prostate. Cancer Epidemiol. Biomarkers Rev. 22, 898-904.
36. de Santana I.A., Moura G.S., Vieira N.F., Cipolotti R. (2008) Metabolic syndrome in patients with prostate cancer. Sao Paulo Med J 126, 274-278.
37. Scott J.A. & King G.L. (2004) Oxidative stress and antioxidant treatment in diabetes. Ann. N. Y. Acad. Sci. 1031, 204-213.
38. Shapiro E., Hartanto V. & Lepor H. (1992) Quantifying the smooth muscle content of the prostate using double immunoenzymatic staining and color assisted image analysis. J. Urol. 147, 1167-1170.
39. Stewart S.B. & Freedland S.J. (2011) Influence of obesity on the incidence and treatment of genitourinary malignancies. Urol. Oncol. 29, 476-486.
40. Tuxhorn J.A., Ayala G.E., Smith M.J., Smith V.C., Dang T.D. & Rowley D.R. (2002) Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin. Cancer Res. 8, 2912-2923.
41. Vignozzi L. & Maggi M. (2014) Prostate cancer: intriguing data on inflammation and prostate cancer. Nat Rev Urol. 11, 369-370.
42. Vignozzi L., Morelli A., Sarchielli E. et al. (2012) Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit. J. Endocrinol. 212, 71-84.
43. Vignozzi L., Gacci M., Cellai I. et al. (2013) Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation. Prostate 73, 789-800.
44. Vignozzi L., Rastrelli G., Corona G., Gacci M., Forti G. & Maggi M. (2014) Benign prostatic hyperplasia: a new metabolic disease? J. Endocrinol. Invest. 37, 313-322.
45. Vikram A., Kushwaha S. & Jena G.B. (2011) Relative influence of testosterone and insulin in the regulation of prostatic cell proliferation and growth. Steroids 76, 416-423.
46. Vilamaior P.S.L., Tabora S.R. & Carvalho H.F. (2006) Postnatal growth of the ventral prostate in Wistar Rats: a stereological and morphometrical study. Anat. Rec. A Discov. Mol. Cell. Evol. Biol. 288, 885-892.
47. Weeks I., Sturgess M.L. & Woodhead J.S. (1986) Chemiluminescence immunoassay: an overview. Clin. Sci. 70, 403-408.
48. Xu P., Wang Y., Piao Y. et al. (2001) Effects of matrix proteins on the expression of matrix metalloproteinase-2, -9, and -14 and tissue inhibitors of metalloproteinases in human cytotrophoblast cells during the first trimester. Biol. Reprod. 65, 240-246.
49. Zimmermann D.R., Dours-Zimmermann M.T., Schubert M., Bruckner- Tuderman L. (1994) Versican is expressed in the proliferation zone in the epidermis and in association with the elastic network of the dermis. J. Cell Biol. 124, 817-825.